Compensation is one such suggested mechanism of tumor resistance specific to mTORC1 targeting, wherein the inhibition mTORC1 normally exerts on the PI3K/Akt pathway is countered by pharmacological intervention with mTORC1 inhibitors, paradoxically leading to overactivation within the pathway [34]. The gene discussed is AKT1; the disease is neoplasm.